USANA Health Sciences (NYSE:USNA) Given New $36.00 Price Target at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price target lowered by DA Davidson from $38.00 to $36.00 in a report issued on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.83 EPS, FY2025 earnings at $2.57 EPS and FY2026 earnings at $2.68 EPS.

A number of other analysts have also recently weighed in on the stock. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Trading Down 14.0 %

Shares of NYSE:USNA opened at $28.57 on Thursday. The stock has a market capitalization of $544.54 million, a PE ratio of 10.10, a P/E/G ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32. The firm has a fifty day moving average price of $33.50 and a 200 day moving average price of $36.56.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. On average, sell-side analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new position in USANA Health Sciences during the fourth quarter worth $28,000. Safe Harbor Fiduciary LLC acquired a new stake in USANA Health Sciences in the 3rd quarter worth $30,000. KBC Group NV increased its holdings in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP bought a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $132,000. 54.25% of the stock is owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.